Vaxcyte (PCVX) Accumulated Depreciation (2019 - 2023)

Vaxcyte (PCVX) has reported Accumulated Depreciation for 5 consecutive years, with $9.3 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Accumulated Depreciation rose 51.58% year-over-year to $9.3 million; the TTM figure through Dec 2023 stood at $9.3 million (up 51.58% YoY), while the FY2023 annual figure was $9.3 million, up 51.58% from the prior year.
• Accumulated Depreciation climbed to $9.3 million in Q4 2023 per PCVX's latest filing, from $8.4 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $9.3 million in Q4 2023 and bottomed at $3.0 million in Q4 2019.
• Historically, Accumulated Depreciation has averaged $5.3 million across 5 years, with a median of $4.8 million in 2021.
• Annual changes were most pronounced in 2021 — Accumulated Depreciation slipped 13.4% — and 2022, when it soared 72.41%.
• Vaxcyte's Accumulated Depreciation stood at $3.0 million in 2019, then surged by 37.39% to $4.1 million in 2020, then slipped by 13.4% to $3.5 million in 2021, then soared by 72.41% to $6.1 million in 2022, then soared by 51.58% to $9.3 million in 2023.
• Business Quant data shows PCVX's Accumulated Depreciation at $9.3 million in Q4 2023, $8.4 million in Q3 2023, and $7.6 million in Q2 2023.